Cargando…

Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway

Rotavirus enteritis (RVE) is a common acute intestinal infectious disease caused by rotavirus infection. It is an important cause of death in children younger than 5 years worldwide. Shenling baizhu powder (SBP), a classic traditional Chinese formulation, is one of the most popularly prescribed medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoyan, Yang, Qian, Zhou, Xiaofeng, Chen, Ting, Dou, Liwen, Wang, Furong, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062900/
https://www.ncbi.nlm.nih.gov/pubmed/33897431
http://dx.doi.org/10.3389/fphar.2021.642685
_version_ 1783681860268720128
author Wang, Xiaoyan
Yang, Qian
Zhou, Xiaofeng
Chen, Ting
Dou, Liwen
Wang, Furong
Wang, Wei
author_facet Wang, Xiaoyan
Yang, Qian
Zhou, Xiaofeng
Chen, Ting
Dou, Liwen
Wang, Furong
Wang, Wei
author_sort Wang, Xiaoyan
collection PubMed
description Rotavirus enteritis (RVE) is a common acute intestinal infectious disease caused by rotavirus infection. It is an important cause of death in children younger than 5 years worldwide. Shenling baizhu powder (SBP), a classic traditional Chinese formulation, is one of the most popularly prescribed medicines for digestive diseases. Clinical studies have revealed the protective effects of SBP on RVE. However, the potential mechanism is still unclear. In this study, we aimed to evaluate the anti-rotavirus effect of SBP and its mechanism, focusing on the TLR4/MyD88/NF-κB signaling pathway. Our results demonstrated that, based on the inhibition of the virus-induced cytopathic effect in Caco-2 cells, the concentration for 50% of maximal effect (EC(50)) and selectivity index (SI) of SBP for RV-SA11 in the serum were 5.911% and 11.63, respectively. A total of 219 active compounds with oral bioavailability ≥30% and drug-likeness ≥ 0.18 were selected from the 10 ingredients present in the formulation of SBP, which acted on 471 potential targets. A total of 226 target genes of RVE were obtained from the GeneCards database. The protein-protein interaction (PPI) network showed that there was a close interaction between 44 common targets of SBP and RVE. The results of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that SBP acted on RVE through various inflammatory pathways and the intestinal immune network. Subsequently, we investigated the effect of SBP on TLR4/MyD88/NF-κB signaling pathway in vitro. After infection with RV- SA11, the expression of TLR4, MyD88, and NF-κB mRNA and protein increased significantly, which could be abolished by SBP treatment. In addition, the IL-1β, TNF-α, IL-6, and IFN-β levels increased markedly in Caco-2 cells infected with RV-SV11. Treatment with SBP partly reversed the changes of IL-1β, TNF-α, and IL-6, while further increased the level of IFN-β. In conclusion, our study revealed that SBP can significantly inhibit rotavirus replication and proliferation in vitro. The antiviral effect may be related to the regulation of the TLR4/MyD88/NF-κB signaling pathway, followed by the down regulation of inflammatory cytokines and up regulation of IFN-β induced by rotavirus.
format Online
Article
Text
id pubmed-8062900
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80629002021-04-24 Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway Wang, Xiaoyan Yang, Qian Zhou, Xiaofeng Chen, Ting Dou, Liwen Wang, Furong Wang, Wei Front Pharmacol Pharmacology Rotavirus enteritis (RVE) is a common acute intestinal infectious disease caused by rotavirus infection. It is an important cause of death in children younger than 5 years worldwide. Shenling baizhu powder (SBP), a classic traditional Chinese formulation, is one of the most popularly prescribed medicines for digestive diseases. Clinical studies have revealed the protective effects of SBP on RVE. However, the potential mechanism is still unclear. In this study, we aimed to evaluate the anti-rotavirus effect of SBP and its mechanism, focusing on the TLR4/MyD88/NF-κB signaling pathway. Our results demonstrated that, based on the inhibition of the virus-induced cytopathic effect in Caco-2 cells, the concentration for 50% of maximal effect (EC(50)) and selectivity index (SI) of SBP for RV-SA11 in the serum were 5.911% and 11.63, respectively. A total of 219 active compounds with oral bioavailability ≥30% and drug-likeness ≥ 0.18 were selected from the 10 ingredients present in the formulation of SBP, which acted on 471 potential targets. A total of 226 target genes of RVE were obtained from the GeneCards database. The protein-protein interaction (PPI) network showed that there was a close interaction between 44 common targets of SBP and RVE. The results of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that SBP acted on RVE through various inflammatory pathways and the intestinal immune network. Subsequently, we investigated the effect of SBP on TLR4/MyD88/NF-κB signaling pathway in vitro. After infection with RV- SA11, the expression of TLR4, MyD88, and NF-κB mRNA and protein increased significantly, which could be abolished by SBP treatment. In addition, the IL-1β, TNF-α, IL-6, and IFN-β levels increased markedly in Caco-2 cells infected with RV-SV11. Treatment with SBP partly reversed the changes of IL-1β, TNF-α, and IL-6, while further increased the level of IFN-β. In conclusion, our study revealed that SBP can significantly inhibit rotavirus replication and proliferation in vitro. The antiviral effect may be related to the regulation of the TLR4/MyD88/NF-κB signaling pathway, followed by the down regulation of inflammatory cytokines and up regulation of IFN-β induced by rotavirus. Frontiers Media S.A. 2021-04-09 /pmc/articles/PMC8062900/ /pubmed/33897431 http://dx.doi.org/10.3389/fphar.2021.642685 Text en Copyright © 2021 Wang, Yang, Zhou, Chen, Dou, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Xiaoyan
Yang, Qian
Zhou, Xiaofeng
Chen, Ting
Dou, Liwen
Wang, Furong
Wang, Wei
Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title_full Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title_fullStr Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title_full_unstemmed Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title_short Shenling Baizhu Powder Inhibits RV-SA11-Induced Inflammation and Rotavirus Enteritis via TLR4/MyD88/NF-κB Signaling Pathway
title_sort shenling baizhu powder inhibits rv-sa11-induced inflammation and rotavirus enteritis via tlr4/myd88/nf-κb signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062900/
https://www.ncbi.nlm.nih.gov/pubmed/33897431
http://dx.doi.org/10.3389/fphar.2021.642685
work_keys_str_mv AT wangxiaoyan shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT yangqian shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT zhouxiaofeng shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT chenting shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT douliwen shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT wangfurong shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway
AT wangwei shenlingbaizhupowderinhibitsrvsa11inducedinflammationandrotavirusenteritisviatlr4myd88nfkbsignalingpathway